PR E/A, PVR 1, 2, 2, 3, 3, 3, 3, 4, 5, 2 1, 2, 3, 4, 5,ASE, ,21 54, sniff 5 5,2 ASE,, 21 mm 20 sniff 50 3 mmhg, 21 mm 20 sniff mmhg, 8 m
|
|
|
- らむ たみや
- 5 years ago
- Views:
Transcription
1 , 2, 2, 2, 3, 3, 2, 4, 5, 4 1, 2, 3, 4, 5 I PH, PH PrePH PH PostPH, LVEF PostPH PEF-PostPH, PrePH PEF-PostPH, 25 mmhg, LVEF 45, 27, 15 mmhg PrePH mmhg PEF-PostPH 13 TomTec 2D CPA, St PrePH,PEF-PostPH, St / St vs ,p , St / St vs ,p , St / St vs ,p PrePH PEF-PostPH ROC, St / St 0. 85, St / St 0. 80, St / St 0. 93, St / St, , 86,PrePH PEF-PostPH 1, 2, 2, 2, 3, 3, 3, 3, 4, 4 1, 2, 3, 4,, PR a, - DPGA PR, A, TAPE AC,DPGA PR /TAPE AC,,, RVEDP, 49 DPGA PR TAPE AC,DPGA PR /TAPE AC, A RVEDP DPGA PR A r =0. 74,p , RVEDP r =0. 52,p , DPGA PR /TAPE AC RVEDP r =0. 80,p DPGA PR /TAPE AC,RVEDP 12 mmhg ROC 0. 98, , 91 DPGA PR /TAPE AC,RVEDP. 1, 2, 2, 2, 1, 2, 3, 3, 4, 3 1, 2, 3, 4 1 PVR,,, PAWP CO PVR,,,, PR - RFPG CO ECHO PVR,,, PAWP,, PVR, 46,RFPG, CO ECHO, LAVI, E, E/A,E E/e,, erap E/A,E/e LAVI,E/A PAWP y =6. 6 x+3. 0,r =0. 72,p , PAWP, RFPG + erap 6. 6 E/A + 3 / CO ECHO PVR,PVR r=0. 83,p
2 PR E/A, PVR 1, 2, 2, 3, 3, 3, 3, 4, 5, 2 1, 2, 3, 4, 5,ASE, ,21 54, sniff 5 5,2 ASE,, 21 mm 20 sniff 50 3 mmhg, 21 mm 20 sniff mmhg, 8 mmhg 21 14, 21, mmhg, mmhg, mmhg, sniff mmhg, mmhg, mmhg,, 7 sniff , 7 1 5,sniff ,sniff p =0. 005, 5 p =0. 012,,,,,sniff , 2, 3, 2, 4, 4, 5, 5, 5, 2 1, 2, 3, 4, 5,, PR -, PAWP, AF,AF,PR PAWP,RR PAWP,, 7 AF 15 PAWP RAP 5 PR RR -, RAP epadp. 5, 1 RR PAWP,ePADP 5 r =0. 88,p r =0. 87,p , RR r=0. 91,p Bland-Altman,5 1, RR PR PAWP, RR 1, 2, 3, 2, 4, 4, 5, 5, 5, 2 1, 2, 3, 4, 5, PR RFPG, MPAP, AF.,AF,,,AF RR, RFPG MPAP,, 7, 7 PR AF 15 MPAP. PR 5 RFPG RR RFPG, ASE, empap empap 5, 1 RR RR 1 MPAP. MPAP,, RR 1 empap r =0. 791,p ,5 empap r =0. 787,p =0. 001, 1 empap r =0. 751,p = Bland- 2
3 Altman AF PR MPAP, RR RR 1 1, 2, 3, 2, 1, 1, 1, 1, 3, 2 1, 2, 3 AF, RR RR 1 / RR RR RR 1 / RR 2, AF E DT, s e,20 E e RR RR ms,dt 700 ms RR 0,,s RR 1 RR 1 /RR 2,E,DT,e RR 1,RR 2, RR RR 3,RR 1 / RR 2,s 14 9,e 9 4,E 6 4,DT 10 4 RR 1 / RR 2 1 ICC 44,RR 1 /RR 2 e 0. 97, E/e 0. 94,DT ICC, 1 e 0. 95,E/e 0. 93,DT 0. 86,e E/e,RR 1 / RR 2 s RR 0,AF, RR 0 1, 1, 2, 1, 1, 2, 3 1, 2, 3,, 1 87, ST, SAM MR.,, ST 4, SAM MR 5 MRI 18, Q T 28, 2,,,., MRI, 1 1, 2, 2, 1, 1, 1, 1, 1, 1, 1 1, 2 52,. 28 5,, Japan coma scale JCS 100, 120 /, 111 / 45 mmhg Carbon monoxide hemoglobin CO-Hb 42. 5, CO 100 CO-Hb 6. 4,, 70 / - mmhg, 7 TTE TTE, LVEF 19, FAC 10. CPK 1, 961 ng/ml,ck-mb 3. 4 ng/ml, I 179 ng/ ml,, CO, 8,25 33 hyperbaric oxygen therapy HBOT 2 HBOT TTE, LVEF 55,FAC 34, 8 TTE LVEF HBOT, 24,2 HBOT,CO CO,,TTE 3
4 1, 1, 1, 1, 2, 3, 3, 3, 3, 1 1, 2, 3, 60,9. 2 2,,, 134 / 46 mmhg, mg/ dl,, 75,, TMF, PASP 104 mmhg 61 mm, 5. 1 L/,,,, mm,tmf E/A ,PASP mmhg, mmhg,pasp mmhg, L/,, 39, 1, 2, 2, 2, 3, 3, 3, 3, 4, 4 1, 2, 3, 4 3 3DSTE,, St,,, 3DSTE,,, Artida 3DSTE , 8, 3 St,, E R, E LC, E R E LC /E R,,E R vs S C vs ,E LC vs ,p 0. 01,E LC /E R vs ,p 0. 01,S A vs ,p S A /E R vs ,p ,,,,,. 1, 1, 2, 2, 2, 3, 1 1, 2, 3,,, 30,,,.,.2D, RCC, jet LCC, NCC RCC,,3D, RCC-LCC,RCC-NCC, doming 3D,,LCC-NCC, raphe RCC,, 2D 3D,,,, 3D S C S A,S A E R S A /E R, St 4
5 1, 1, 1, 1, 1, 1, 2, 2, 2, 2 1, 2 AS TAVI, AVR, TTE TAVI AVR TAVI AVR TTE. AS TAVI AVR, 1 TTE 35 AVR 80,,, TTE TAVI 17 47,AVR 18 20, TAVI 87 IQR; 82 89, AVR 82 IQR; TTE, EF TAVI AVR vs. TAVI: IQR; vs IQR; ,P=0. 02, AVA AVR vs TAVI: cm 2 IQR; cm 2 vs cm 2 IQR; cm 2, p=0. 16, LVMI AVR vs. TAVI: 122 g/m 2 IQR; g/m 2 vs. 131 g/m 2 IQR; g/m 2, p=0. 34, TTE,EF p=0. 99 LVMI AVR vs TAVI: -24 g/m 2 IQR; g/m 2 vs. -25 g/m 2 IQR; g/m 2, p=0. 78,AVA AVR,TAVI AVR vs. TAVI: cm 2 IQR; cm 2 vs cm 2 IQR; cm 2,p ,TTE, TAVI AVR 1, 2, 2, 1, 1, 1, 1, 1, 1, 2 1, ASD, CTR 53 TTE,ASD,, 10 mm,qp/qs 1. 5,, 37 mmhg, IVC TTE, 9. 1 mm Valsalva 2 mm , Qp/Qs 1. 4, 22 mmhg,tte IVC 15 mm Amplatzer septal occluder,valsalva 25 mm Cribriform occluder, IVC device TTE,,,, 3.,ASD, , 3, 4, 3, 1 2, 4, 1 2, 1 2, 1, 1 1, 2, 3, 4,, ACHD 1974,1998, , ,,,, ACHD,ACHD ,,, 1, ACHD,,,,,,, ACHD,, 5
6 1, 2, 1, 2, 2, 2, 3, 3, 2, 1 1, 2, 3,, RVF, PE,RVF 28 6 PE bpm, g/m2 PE, 8 mm,rvf continuous pattern 32 3, 48 bpm, 25 mm, RVF biphasic pattern 160 bpm, 201 mmhg,1, 124 g 1 AST 162 U/L,ALT 185 U/L, 5 90 bpm, g/ m2, 12 mm,rvf continuous pattern, 8, PE, RVF, PE 1 2, 3, 1 2, 1 2, 1 2, 2, 3, 1, 1, 1 1, 2, 3 venous impedance index VII, 1,,, HT DM 34 N 39,HT 15,DM 10 HT DM HT-DM 9 GE LOGIQ E9,,, resistive index RI.,,, VII egfr, HT,DM HT-DM 3 N,eGFR, 3 RI 3 VII DM HT-DM N HT, VII 34, RI egfr r = , VII egfr RI, VII,, DM VII,,DM 1, 2, 1, 3, 3 4, 3, 5, 6, 3, 7 1, 2, 3, 4, 5, 6, 7 DVT, SV DVT, SV, DVT SV, DVT DVT SV,, SV, , SV DVT DVT. DVT 11 SV, mm, DVT mm mm, p 0. 01, SV DVT mm, DVT mm, mm 3 p= DVT SV,, DVT DVT, SV 1, 1, 2, 2, 2, 3, 3, 4, 4, 4 1, 2, 3, 4, Ebstein, 6
7 , STIC spatiotemporal image correlation 3 1,,. 3, ,, 2, STIC 2,.In vitro,,, 2, 10 m 1,,, 10,, 30 G 0. 5 mm, m, DSPC 1, 2-distearoyl-sn-glycero-3-phosphocholine 10, 2 1 MHz, 50, 80 V,, 1 m 5 m, 5 m., 10,,, HIFU.,,HIFU,,HIFU, W/cm 2,HIFU W/cm mm, 100 mm, MHz HIFU 10 W,50 W,100 W 3, 1 HIFU Fig. 1 a, 1 Fig. 1 b, 1,,,, 1, 2 3, 1, 1, 1, 2 3, 2, 4, 1 1, 2, 3, 4 CT, MR,FDG-PET PET, US US PET ,,US PET, Philips IU 22 / HD 11,GE LogiqE MHz.US 1 7 mm, 2 L/T ratio; 2, 3, 4, 5, 6 6,PET SUVmax 2. 5,US PET ROC McNemar US AUC, , , 7
8 , , ,3 3, 25, 5, 2, 3,PET 24, 5, 3, 3 US PET 92. 6, 88. 9, 63. 0,63. 0, 85. 7,82. 9, 89. 0,89. 0, 71. 0,63. 0 US,PET 1, 2 3, 1 2, 1 2, 2 3, 4, 5 1, 2, 3, 4, 5 RA,,,,,, US, US US 1 1, T 1 LTR env px env px 3 5 GE Logiq e Premium, 22 MHz,B mode,. env-px 1 1, env-px US,env-pX 2 2 env-px 1, US. 1, 1, 1, 1, 1, 2 1, 2 FMC Turner X 1, 2 3, 000 1,Turner 9,,22 trisomy Down,Turner 1 cystic hygroma, Turner,,,,, 1, 1, 1, 1, 1, 2 1, 2,,,, Sonazoid Aplio500 Superb Micro-vascular Imaging SMI, SMI,, SMI 50 fps 2, Smart 3D SMI 3D, 3D Fusion 3D,B-mode volume rendering VR, volume data, 3D,, 1, 1, 1, 1, 1, 2 1 JA, 2 JA, EOB-MRI, 81. 9,Sonazoid, 8
9 B,,,, 3,,, ,,, 19 19,, 19 15, , 9. 7 mm, EOB-MRI, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 1 1, 2 71,, 2 9 kg, CT, IgG4 1, 190 mg/ dl IgG4, CT S 8 S 6 2 cm, MRI T 1 WI,T 2 WI, IgG4,,,,,IgG4,CT,,,,IgG4,,,,,, ELISA 0. 6,2,, CT, 30 mm MRI T 1,T 2, DWI EOB MRI wormeaten defect Em18 AEL.,,,AEL ELISA 0. 6,2,, CT, mm, worm-eaten defect,em18, AEL AEL 45, 1,, irregular echogecic pattern,b mode, 2,,, artifact,b mode AEL 2, 1, 3, 2, 1, 1, 1, 1 1, 2, 3, MRI Shear wave elastgraphy SWE, SWE SWE 153, 149,SWE Vm Fibrosis-4 FIB-4 index, Asparate aminotransferase-platelet index APRI,, 4 149,LOGIQ E9, C 1-6 XD clear, Depth 8 cm, 10 Vm ROI,, 79 70, 66, B 31,C, 41, 77, / L,AST IU/L,ALT IU/L, Alb 4. 0 g/dl,t-bi mg/dl,fib-4 index 2. 25,APRI Vm m/s,fib-4 index r=0. 49, p 0. 01,APRI r = ,p
10 ., r = ,p AST 167 IU/L,p= ,ALT 164 IU/l,p= ,FIB-4 index 5. 8,p= ,APRI 2. 12,p= SWE FIB-4 index,apri, SWE,, 2 1, 46,.,.,, FFT, Vmax cm/s,vmin 3. 0 cm/s, 9. 5 cm/s cm/s, Vmax cm/s, Vmin 6. 6 cm/s, CT,, to-and-fro.,,,,,,, 80, CT, 3 cm, 3, CT.,, CT,, CT fusion,,,,,,, 10 CT,,, CT, air,, CT fusion,,,, 0. 05, CT fusion,,,,,,, 80,,, CT,, WBC 16, 600,CRP 26, CT, mm,,,,,, squareshaped,,,,,.,,,.,,,,,, 78,, square-shaped,, 1, 2, 2, 2, 3, 3, 4 1, 2, 3, 4 60,., 10
11 10 mm,,,,, 10 mm 14 mm,, 7,,,,,,,,,,,, EUS FNA, IPMN ,,,2015 CT, DUPAN 2 3, 610 U/ml,CT 15 mm Late phase MRI,T 2 Duct penetrating sign, EUS CT, high/low echo, Spot, 5, EUS-FNA ClassIII,,,IPMC,IPMN, modality EUS.,,,,,,,,,, ML, / EUS-FNA ML EUS-FNA EUS FNA ML , 15 : 18.ML, in situ hybridization FISH FCM 1.,2.EUS FNA,3.,4., , 2, mm ML B DLBCL 19, FL 9, HL 2,MALT MALT 2, IBCL G 22 67,22 G 11 33, 2, 28, 11, , FISH/FCM 4.EUS-FNA ML 27 82, DLBCL 15 79,FL 9 100, HL 0 0,MALT 2 100,IBCL , 2 DLBCL, 2 DLBCL, 2 HL 5. ML EUS-FNA, 94, 82,,HL 1, 2, 1, 1, 1, 1, 1 1, 2 US , US, CT,. Aplio 500 / XG/ XV. PVT 375 BT/ 674 BT/ 704 SBT ,10 2.,, 5 4, 1, 54. 5, US / 44, 537 US 80 4 / 5 3, 1, 1., 3, 1, mm mm US 10 mm m 2,, 11
12 , 2 US mm 10 mm,m, US 3,US US 12
092_41-1_23九州CS6_責.indd
2013 10 6 1, 2 3 4, 5, 4, 6, 3, 5, 1, 1 1, 2, 3, 4, 5, 6,70. 2011 7 CT, B C, -GTP,CEA CA 19-9.US,S 2 / 3 43 37 mm,. 11 mm,,.ceus,.,.,. 1, 1, 1, 1, 1, 1, 1, 1, 1, 2 1, 2 52. S 7 20 mm,. CT, CT, EOB MRI,T
049_41-1_43北海道CS6_念*.indd
25 10 19 11 : 00 18 : 00,,,,, Meyer et al. Circulation 2010;121:252-258,ASE J Am Soc Echocardiogr 2010;23:685-713., ASE 3 1, 10, 2 36, 3 38.ASE TAPSE,RVFAC,S. 1 / 2 / 3 TAPSE 8. 4 / 10. 0 / 24. 4 mm 16
41-6_50回中国地方会Pr6N__HP掲載用.indd
2014 9 6 1, 2, 2, 2, 2 1, 2 60.. CT S 5 47 mm, 20 mm. US,,..,,. CT.,,.,. 8.,,.,. 1, 2, 2, 2, 2, 2, 3, 3 1, 2, 3 70 5,, CT. 17, 20, 30..,. Segmental Arterial Mediolysis SAM,.,. SAM,., 50,.,, 70. S 5 SOL.
169_39-2_23関東甲信越_念*.indd
2011 10 29 30 TFT infective endocarditis IE IE vegetation 10 20 IE IE Duke 1 1 1 1 2 2 1 2 1 1 5 US 1 mammography MMG 2 2 a second look US 0. 4 mm US b MMG 17 15 US MMG cse ASVascularity SE AS Vascularity
42-2_26回関東甲信越地方会Pr6N_念*.indd
2014 10 18 19 TFT acoustic radiation force ARALA TI MI TI / MI TI / MI 1 2 3 4 5 1 2 3 4 5 PZT MASON 20 MRayl 20 MRayl 10 500 khz 20 MHz 1 mw 15 W 500 khz 20 MHz 100 W 60 MHz 1 2 3 4 5 4 6 6 4 1 2 3 4
084_41-1_23四国CS6_念*.indd
2013 10 5 The forgotten chamber.,,,.1.2,,, 3,,. 4,CT,MRI,,,,,,,, fractional area change: FAC,,M tricuspid annular plane systolic excursion: TAPSE TAPSE < 16 mm., s, speckle tracking, Tei index,,,.,,,.,6,.,,,,,
Microsoft Word - 平成24年度医学部卒業試験問題-2.docx
24 2012.10.25 13:00 15 00 5 2 10 20 60 80 110 10 1 6 7 /kg 1 12 20 30:2 AED 3 1 2 119 2 2 2 X X SpO 90% 60mmHg Primary Survey FAST CT 90% 100mmHg FAST 1 2L FAST(Focused assessment with sonography for trauma)
04_ポスター.indb
般ポスター基礎超音波計測一般 一般ポスター基礎 6 月 8 日 ( 金 ):00 - :0 ポスター会場 ( 神戸ポートピアホテル B F 座長 : 9- 基 P-00 S790 9- 基 P-00 S790 9- 基 P-00 S79 Jing ZHU, 9- 基 P-00 S79 9- 基 P-005 S79 9- 基 P-006 CT S79 Wenjing WU 9- 基 P-007 HIFU
慈大呼吸器_25-1_02T_CS5.indd
ISSN 0919-6870. Jikei Journal of Chest Diseases Jikei University Chest Diseases Research Association 82 1 1 1 1 1 1 1 1 2 1 2 74 2010 2 2011 8 12 2012 1 17 1 20 1 28 CT 5 / 50 2011 8 2 / 1200 mg/2x 40
21 5 I C T J-Doit High risk Risk 20 7 21 34,324 30,858 38,735 26,800 27,490 20,472 18,533 20,096 14,913 14,931 488 470 491 435 446 10 t-pa intervention t-pa interventionclipping simulator subspecialty
02-06プ_一般ポスター_0407.indd
一般ポスター工学基礎一般ポスター工学基礎 イメージング 信号処理 5 月 7 日 ( 土 )6:0-7:0 ポスター 展示会場 座長 : ( 栃木県総合文化センター 階第 4 ギャラリー ) 90- 基 P-00 CT S6 90- 基 P-00 S6 90- 基 P-00 S6 90- 基 P-004 S6 90- 基 P-005 S64 90- 基 P-006 S64 90- 基 P-007 STC
untitled
1 ... 3... 3... 3... 4...13...16...18...20...22 2 PTPE 3 PTPE CT Grade 2 A PTPE PTPE 4 A S 3 3 B H3,P1,N1,M1, LM0, R23 15 20gS, ptype 3, 60 x 50mm, pt4b/siurinary bladder, int, INF, ly2, v1, ppm070mm,
/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg
17 2005/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 32 5/8 36.1 :90 /:114/64 mmhg 166.2 cm64.3 kg 3.9 g/dl 1.6 g/dl 382 mg/dl 408 mg/dl
1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
03_一般.indb
基礎一般口演 一般口演基礎 マイクロバブル キャビテーション 6 月 8 日 ( 金 )8:0-9:0 第 会場 ( 神戸ポートピアホテル B F 生田 ) 座長 : 9- 基 -00 S566 Marie Pierre KRAFFT 9- 基 -00 S566 Marie Pierre KRAFFT Institut Charles Sadron CNRS, University of Strasbourg
41-6_35回中部地方会Pr6N_HP掲載用.indd
₃₅ 2014 9 7 ₃₅ ₁ 1, 1, 2, 1, 1, 1, 3, 3, 3 1, 2, 3., e E E/e. CT 158,CT Volume data, CT -140-40 HU. E e, e E/e. e,e/e,. ₃₅ ₂ 1, 1, 1, 1, 2, 2, 3, 2, 2 1, 2, 3 82, T,.. S, 13 mmhg,,, 10γ S 260 mmhg,. S,.,
₂₈ TFT 1 ₁ ₁ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B-Flow,., B-Flow B Flow. 2, , 2, 3.,,. Logiq S8 GE. ₁ ₂ 1, 1, 1, 1, 2, 3, 3, 3
₂₈ 2016 10 22 23 TFT 1 ₁ ₁ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B-Flow,., B-Flow. 3. 1 B Flow. 2,. 3. 3 1, 2, 3.,,. Logiq S8 GE. ₁ ₂ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B.,.,,.,,. Depth 6 cm..,,,,.,. ₁ ₃,,,. 3,.3
抄録_46回中国地方会37-6_責.indd
46 22 9 11 Update 46-1 Gd-EOB-DTPA MRI EOB-MRI HCC dysplastic nodule DN 146 62 146 123 HCC 23 DN B hypoechoic 67 46%hyperechoic 79 54% bright loop 14% A dynamic MDCT iso density EOB-MRI 24 B CT low density
08症例報告4山内.indd
症例報告 37 急性大動脈解離に対する上行大動脈置換術後の大動脈基部拡張 大動脈弁閉鎖不全に対する自己弁温存基部置換術 (remodeling 手術 ) 概要 : mm remodeling 索引用語 : remodeling Remodeling technique for aneurysm of aortic root and moderate aortic valve regurgitation
抄録36-6偶_中国_責.indd
45 21 9 12 1 45-1 3D 1 5 10 1 1 12 0 13 6 2D 2 2 3D 1 14 2 63g 11cm 2 3D x 3DCT 1 3D 45-2 FIUVV 3 10 FIUVV IUFD 2 FIUVV 33 35 MRI 36 8 22 1cm FIUVV 28 IUFD 45-3 Fetal intra-abdominal umbilical vein varixfiuv
表紙030313.PDF
H2 CO (1) (3) (4) () () ( ) ( : 11 ) [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ]......... [ ] [ ] [ ] [ ] [] [ ] [ ] [ ] [ ] (g) [ ] ) [ ] [ [ ] [ ] [ ] ) ) ) )... [ ] [] [ ] [] [ []........
肝臓病教室201207v2配布用.pptx
24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0
デスフルラン
デスフルラン時代の周術期管理 岡山大学麻酔科蘇生科森松博史 デスフルランの特徴!!! 岡山大学での現状 本日のお話 デスフルランの特徴 3 Eger et al. Anesth Analg 1998; 86: 414-21 デスフルランの特徴 2 つのメタアナリシス 2005 Macario et al. Am J Health Syst Pharm!! 2010 Dexter et al.
油圧1.indd
4 2 ff f f f f f f f f f f f f ff ff ff r f ff ff ff ff ff ff R R 6 7 φφ φφ φφ φ φ φφ φφφφφφφφ φφφφ φφφφ φφ! φ f f f f f f f f f f 9 f φ φ φ φ φ φ φ φ φφ φφ φ φ φ φ SD f f f KK MM S SL VD W Y KK MM S SL
untitled
- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 -
0 1
9 - -R -V -K - -V - -V 3 0 3 3 3 001 0 001 00 0 00 1 0 11 1 0 11 10 00 0 10 00 0 0 1 3 F X1CE G XCE CV Cm H X111CE C1V Cm C1.W J X1CE CV CV Cm E X1CE C1V Cm K X11CE C1V m V L X11BCE CV m 1.W C90V M XCE
125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
救急車同乗実習レポート 総括
14 9 1 9 10 10 19:00 23:00 52 1 6.5 40 CT X CT Ope 15 /min BP 100/70mmHg HR 96 /min O U m 60 25/min BP 140/80mmHg HR 55 O Spo 98 BP 172/68mmHg O 30 15 /min BP 100/60mmHg HR 80 /min BS O O CO 30 40 JCS
12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36
訪問入浴Ｑ＆Ａ PDFファイ ル httpwww.care-mirai.commiraihomehelpe_buth.html.docx
4 450kg500kg 185cm 95kg 100kg 185 ( ) Vision , 40 8/138/15 1/11/3 1 13,000 11,700 9,500 3,500 13,000 11,700 9,500 3,500 http://www.care-mirai.com 1 37 38 1 1,000PPM soda premium 1,100ppm http://www.care-mirai.com/mirai/carbonated.html
無印良品 2012 自転車 カタログ
26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417
S22 vol. 38 Suppl. 2013 38-3-2 38-3-3 38-3-4 38-3-5 JA 4 6 15 14:35 15:15 3 38-4-1 1 JA 38-4-2 10 38-4-3 38-4-4 5 5 6 15 15:20 16:10 3 38-5-1 1 38-5-2
vol. 38 Suppl. 2013 S21 1 6 15 11:25 12:15 4 38-1-1 38-1-2 US 38-1-3 1 38-1-4 38-1-5 2 6 15 13:40 14:30 3 38-2-1 1 38-2-2 38-2-3 CHI-Q 38-2-4 1 38-2-5 IgG4 3 6 15 13:40 14:30 4 38-3-1 S22 vol. 38 Suppl.
4.11 4 55 4.12 11 56 4.13 0 57 4.14 1 58 4.15 4 59 4.16 11 60 5 5.1 5.1 5.2 1 (1983) Q = K A I v = Q / A = K I v = v / o n o Q A L 3 T -1 I : K : LT -1 v LT -1 v LT -1 o n o 61 (3) 5.3 1 5.1 K=10-1 10-3
C VECS C F M kg A E W kg I A R. R. Gkg MGD MGD MGD MGD SPKMGD MGD MGD SPK SPK MGD MMP MMP MMP kg mmhg Intrascleral prosthesis : ISPISP ISP ISP ISP ISP ISP ISP ISP ISP mm mm ISP mm min mm min ISP mm min
) km 200 m ) ) ) ) ) ) ) kg kg ) 017 x y x 2 y 5x 5 y )
001 ) g 20 g 5 300 g 7 002 720 g 2 ) g 003 0.8 m 2 ) cm 2 004 12 15 1 3 1 ) 005 5 0.8 0.4 ) 6 006 5 2 3 66 ) 007 1 700 12 ) 008 0.315 ) 009 500 g ) kg 0.2 t 189 kg 17.1 kg 010 5 1 2 cm 3 cm )km 2-1 - 011
64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () m/s : : a) b) kg/m kg/m k
63 3 Section 3.1 g 3.1 3.1: : 64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () 3 9.8 m/s 2 3.2 3.2: : a) b) 5 15 4 1 1. 1 3 14. 1 3 kg/m 3 2 3.3 1 3 5.8 1 3 kg/m 3 3 2.65 1 3 kg/m 3 4 6 m 3.1. 65 5
C-1 210C f f f f f f f f f f f f f f f f f f f f r f f f f f f f f f f f f f R R
4 5 ff f f f f f f f f f f f f ff ff ff r f ff ff ff ff ff ff R R 7 b b ï φφ φφ φφ φ φ φφ φφφφφφφφ φφφφ φφφφ ù û û Æ φ ñ ó ò ô ö õ φφ! b ü ú ù û ü ß μ f f f f f f f f f f b b b z x c n 9 f φ φ φ φ φ φ
02_特別_共同_奨励.indb
特別プログラム 2 領域横断特別プログラム 知を究める領域横断 シンポジウム領域横断 超音波で全身を見る 6 月 8 日 ( 金 )0:5 - :45 第 9 会場 ( 神戸ポートピアホテル B F 偕楽 2) 座長 : 9 知 -SY- 領 0 S80 2 2 9 知 -SY- 領 02 S80 9 知 -SY- 領 0 S8 9 知 -SY- 領 04 S8 2 2 9 知 -SY- 領 05
★プログラム並べかえ.indb
1 2 3 1 S180 S181 S182 S183 2 3 S184 S185 MRI S187 S188 S189 1 2 1 2 S 37 B flow imaging 1 1 1 2 1 1 S190 2 IVUS 1 2 3 4 5 1 2 S191 3 4 5 : MDCT MRI DSA S192 1 1 1 2 1 2 MR MRI FUS HIFU S194 S195 S196
untitled
1 Contents 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 2 1. 2. 3 3. 1 2 4 4. () () 5 4. 6 5. 7 6. 8 7. 1. 2. ( ) 3. 8 9 1. 1. 2. ( 2. (( ) ) 3. 3. 4. 4. 5. (PMV) ( ) 5. (PMV)( ) 6. 7. 20 1. 2. ( ) 3.
(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
Mast Cell Tumor : MCT c-kit MCT F F MCT C c-kit DNA Canine DNA Ver DNA c-kit C c 1275 A G F c.2355 G A DNA F C F C c-kit MCT c-kit DNA MCT Kiel T B kg cm T T Stage a UW25 P MDR1 B L T B L Leptospira L
2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,
24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998
HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly
HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 S S S Phe Val Asn Gln His Leu Cys Gly Ser His Leu
untitled
-1- -2- -4- -5- 20 30 12-6- 8 15 1-7- -8- -9- -10- 40 60-11- -12- 3 4 70 90-13- -14- 2 4 3 5-15- a 3-16- -17- -18- 128 kg 150 200g 100 200g 250 750g 2 1 94 89 89 81 72 390 97 97 83 83 75 97 97 100 86
ONO L 0.03mg/kg/min 1min 0.01mg/kg/min 10min M 0.03mg/kg/min 1min 0.02mg/kg/min 10min H 0.06mg/kg/min 1min 0.04mg/kg/min 10min 3 1) LSD p=0.000
ONO-1101 7 L 0.03mg/kg/min1min0.01mg/kg/min10minM 0.03mg/kg/min1min0.02mg/kg/min 10minH 0.06mg/kg/min1min0.04mg/kg/min10min 3 1) LSD p=0.0001) 30 2) FACCFSVcfc LVESWS EDA DT MH LSD p
新入_本文.smd
52 28 220 28 4 1 017-777-1511 2 2 8 2 9 8 9 47.2% 12.8% 11.5% 6.0% 4 2 (49.6%)(13.0%) (14.7%) (7.4%)(8.4%) (52.3%)(9.1%) (11.4%) (10.0%) 33.0% 23.4% 15.6% 9.6% (26.0%) (18.3%) (46.5%) (30.0%) (20.0%) 2
23 3 11 14 46 9.0 7 10m 40.1m 15,883 2,681 25 4 10 39 40 800 180 24 2425 22 21 24 5 3 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213
A E A A A A E A E EAE EAE EA AE E AE E A AE EA AE EA AE EA AE EA AE EAE EAE EAE EAE E AE E A AE EA AE EAE E AE EA AE E AE E A AE E E A AE E E A AE EA
A E A A A A E A E EAE EAE EA AE E AE E A AE EA AE EA AE EA AE EA AE EAE EAE EAE EAE E AE E A AE EA AE EAE E AE EA AE E AE E A AE E E A AE E E A AE EA AE EAE EA E AE EA AE EA AE EAE E AE EAE E AE EA AE
200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura,
0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2
24 11 10 24 12 10 30 1 0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 23% 29% 71% 67% 6% 4% n=1525 n=1137 6% +6% -4% -2% 21% 30% 5% 35% 6% 6% 11% 40% 37% 36 172 166 371 213 226 177 54 382 704 216
10 117 5 1 121841 4 15 12 7 27 12 6 31856 8 21 1983-2 - 321899 12 21656 2 45 9 2 131816 4 91812 11 20 1887 461971 11 3 2 161703 11 13 98 3 16201700-3 - 2 35 6 7 8 9 12 13 12 481973 12 2 571982 161703 11
本文／一般演題＿吉田
184 quality of lifeqol mmhg Hb gdl CA Uml Niveau Hb Hb gdl RCC CT MRI T 185 CT A B MRI A:T B:T Douglas red spot S ml RCC 186 A B mg CAUml S MRI A B 187 188 S mg Sampson JA. Intestinal adenomas of endometriosis
BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
32 100 34 51 16,300
32 100 34 51 16,300 - 7 - - 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 1 3 3 5 5 B 6 2 2 4 4 6 10 - - 8 - - - 9 - 20 80 1/3 - - 10 - 0.7 0.9kg 21 147 70-11 - - 50 10cm 50 100 30cm kg 100
32, 15, 3 EUS TIC 1 db,eus EG SR EUS 60, 27, 24 EUS EG SR 0. 11, , EUS EUS EG ₂₆ ₆ 1, 2, 1, 1, 3, 2, 4, 1 1, 2, 3, 4 FibroScan,
₂₆ 2016 10 2 ₂₆ ₁ 1, 2, 2, 2, 2, 1, 2, 5, 3, 4 1, 2, 3, 4, 5., 491,. 491 339, 70 37 152 3, 339 2,.,. ₂₆ ₂ 1, 1, 1, 1, 1, 1, 2, 2, 1 1, 2 Müller MM, LVESVMM LVESV Ees DCM 20 15 CPX,LVESV, Ees,peak- VO 2
10 44 1.2 5 4 5 3 6-1 - 1 2 3 4 5 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 9 10 TEL TEL 1 2 TEL FAX TEL FAX TEL FAX 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 1 2 3 4 5 6 ( ) ( ) 2
急性型から慢性肺血栓塞栓症性肺高血圧症に移行した1例
Japanese Society of Pulmonary Embolism Research -JaSPER- ) MAA 1964 WagnerIio Iio 1965 137 79 58 5715,1SD 99mTc MAA 81mKr discrete defectmpd MDP MPD MDP PH MPD MDP PH PH MDP patchinessmottled
051
June THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 295( 83 ) NTT 1. 2. 3. 4. CHOP-R 5. DNA 1 296( 84 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 3 June 3 1 2003 10 4 1 NTT June THE JAPANESE JOURNAL OF ANTIBIOTICS
180 140 22
21 180 140 22 23 25 50 1 3 350 140 500cm 600 140 24 25 26 27 28 29 30 31 1/12 8.3 1/15 6.7 10 1/8 12.5 1/20 140 90 75 150 60 150 10 30 15 35 2,000 30 32 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 % 100 50 33.3
<82D282A982C1746F95F18D908F57967B95B E696E6464>
1 2 (90cm 70cm 2015) 3 (68cm 28cm 30cm 12kg 2015) (77.5 109.5cm 2015) 4 (22cm 50cm 50cm 4.6kg 2015) (45cm 62.5cm 2015) (47.4cm 62.5cm 2014) 5 (28.5cm 23.5cm) (45cm 62cm 2015) (97cm 107cm 2015) 6 7 8 9
6 12 10661 93100 227213202 222208197 85kg cm 20 64.521 106856142 2 1 4 3 9767 100 35 cm 7747 208198 90kg 23 5828 10661 93100 cm 227213202 10639 61 64.521 85kg 78kg 70kg 61 100 197204.5 cm 15 61
Microsoft Word - 14_LCMS_アクリルアミド
3--2-3-Iodo-2-propynyl butylcarbamate (IPBC) Carbamic acid, butyl-, 3-iodo-2-propynyl ester Iodocarb CAS 55406-53-6 C 8 H 12 NO 2 I C (g/cm 3 ) (mmhg) log P ow 281.09 (280.9910) 64 68 1.51 1.57 (20 C)
がん診療におけるFDG FDG-PET/CTの役割
PET/CT PET/CT MRI PET PET/CT Kurashiki Central Hospital FDG-PET CT PET/CT (stage1) FDG-PET (stage1) PET/CT FDG-PET PET/CT (stage4) FDG-PET (stage4) PET/CT FDG-PET PET/CT PET/CT
72 20 Ope / class Alb g/ cm 47.9kg : /min 112/60m
72 20Ope 68 69 2006 4 50 20 / 52 2006 4 1 2006 4 4 24 class 699.4 5 2 5 23 6 6 15 6 19 6 16 Alb2.03+ 7.5g/ 6 21 153.5cm 47.9kg : 36.7 89/min112/60mmHg (-) (-)S1 S2 S3(-) S4(-) - - 6 15 (+) TP4.9g/dl Alb2.0g/
SIRIUS_CS3*.indd
SIRIUS Innovations SIRIUS SIRIUS Answers for industry. SIRIUS SIRIUS S00 S0 SIRIUS SIRIUS ZX0-ORAZ-0AB0 7.5kW 6 S00 7 8 7.5kW 9 S00 0 8.5kW S0 8.5kW S0 5 6 7 IO-Link AS-InterfaceRT 8 8US 5 6 SIRIUS SIRIUS
緑化計画作成の手引き 26年4月版
http://www.city.shibuya.tokyo.jp/env/en_eventact/midori_ryokka.html 10 11 12 13 14 15 16 17 18 19 P10 P10 1 P12 2635 Fax (1) 47 03-5388-3554 http://www2.kankyo.metro.tokyo.jp/sizen/sinseisyo/e2/tebiki.htm
METs WPW QT LQTS 9Brugada 0 METs 30 Circulation Journal Vol. 67, Suppl. IV,
2002002 Guidelines for Exercise Eligibility at Schools, Work-Sites, and Sports in Patients with Heart Diseases (JCS 2003) JR 2 3 2 3 2 2 3 2 2 3 Circulation Journal Vol. 67, Suppl. IV, 2003 309 2002002
untitled
--...- 2 -...- 2 -...- 2 -...- 3 -...- 3 -...- 7 -... - 11 -...- 13 -...- 16 -...- 17 -...- 19 -...- 20 -...- 22 -...- 23 -...- 27 -...- 28 -...- 31 -...- 33 -...- 39 -...- 42 -...- 43 - ...- 47 -...-
381
P381 P386 P396 P397 P401 P423 P430 P433 P435 P437 P448 P451 P452 381 382 383 384 385 3.0mm 5.0mm 3.0mm 5.0mm SK SK3.0mm SK5.0mm 3.0mm PUR PUR3.0mm 2.0mm 2.0mm3.0mm 2.5mm 2.5mm3.0mm 3.0mm 5.0mm 3.0mm 1.8mm
非 心 臓 手 術 の 術 前 心 精 査 1) 非 心 臓 手 術 死 亡 の30-60%は 心 合 併 症 2) 高 齢 化 社 会 に 伴 い 心 疾 患 をもつ 患 者 の 非 心 臓 手 術 を 受 ける 機 会 が 増 加 術 前 心 精 査 を 担 当 する 循 環 器 内 科 の 役
第 1 回 桜 ヶ 丘 循 環 器 カンファレンス 非 心 臓 手 術 前 に 重 症 大 動 脈 弁 狭 窄 症 が 判 明 した1 例 ~ 高 齢 重 症 AS 患 者 の 現 状 ~ 鹿 児 島 大 学 病 院 心 臓 血 管 内 科 湯 浅 敏 典 非 心 臓 手 術 の 術 前 心 精 査 1) 非 心 臓 手 術 死 亡 の30-60%は 心 合 併 症 2) 高 齢 化 社 会 に 伴
ネオマファーム施工標準軸組構造
注 1 注 2 注 2 SISI 1. 2. 30 35 40 50 15mm 303 (17kg/) 455 16mm, 18mm 250 (20kg/) 455 303 303 _ 6 455 650 10,465 910 2,730 1,820 1,820 910 2,275 1,365 415 450 650
平成25年度調理師試験問題
25 15 60 HB 2 1 1 2 36 1961 46 1971 56 1981 3 1991 3 4-1 - 5 6 7 8 6 2 12 31 1 15 1 15 4 15 4 15-2 - 9-3 - 10 11 12 13 3-4 - 14 腿 15 16 WHO 22 2010 17 18 1-5 - 19 1 g 4 kcal 4 kcal 9 kcal 9 kcal 20 21
14 35H-3 35H-3 15 b f f b b b f f f f f f f f f f b b f f f f f b b b b b b b b b f f f f f f f f f f f f f
bff b b b ff ff ff f f ff b b ff ff f b b b b b b b b b f f f f f f f f f f f f f b b ï ñ ó ff ff ò ô ö ù û û Æ õ ú ü! bõ ú b μ b b b f f f f f f f f f f f f b b bõ fl fi f f f f f f f f b b b b@ b b ff
PC LC8 TLSXB92JC (%) 5 15 25 3 35 (h) : D-SUB : RS-232C WORLD-WIDE OPERATION 142 227 311 142 227 311 (%) 9 7 5 3 1 : LC8 : A14-5-11 5 mm1 m 1 3 5 (%) 142 227 311 142 227 311 TLSXB143JB 7 9 mm TLSXB144JB
Gauss Gauss ɛ 0 E ds = Q (1) xy σ (x, y, z) (2) a ρ(x, y, z) = x 2 + y 2 (r, θ, φ) (1) xy A Gauss ɛ 0 E ds = ɛ 0 EA Q = ρa ɛ 0 EA = ρea E = (ρ/ɛ 0 )e
7 -a 7 -a February 4, 2007 1. 2. 3. 4. 1. 2. 3. 1 Gauss Gauss ɛ 0 E ds = Q (1) xy σ (x, y, z) (2) a ρ(x, y, z) = x 2 + y 2 (r, θ, φ) (1) xy A Gauss ɛ 0 E ds = ɛ 0 EA Q = ρa ɛ 0 EA = ρea E = (ρ/ɛ 0 )e z
M1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1
‹Àfi¡‚¾”O/…_…C…W…F…X…g/01-01
2002 2003 Guidelines for the Diagnosis,Treatment and Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis (JCS 2004) h 1 2 3 1 1 2 2-1 2-2 2-3 2-4 2-5 2-6 2 1 2 2-1 2-2 3 1 2 4 Circulation
43
43 HK4001 X X 1949 Paatero 1 X MTF MTF 10 m 3,6,9mm MTF MTF 3mm,6mm,9mm MTF MTF X HK4004 200nm 950nm 600nm 760nm 850nm 960nm OH 600 900nm 600nm 800nm 44 HK4006 JPEG2000 CTF HK4007 40 X Mo Mo MTF ACR156
04_学術.indd
Arts and Sciences 2 Diagnostic significance of contrast-enhanced ultrasonography for hepatocellular adenoma: experiences of two cases 41080 Key words: Abdominal ultrasonography Contrast-enhanced ultrasonography
02.O...r.A..
8 300ha k (m 3 / / ) (0 2 ) 0405 135 270 2 12 0540 162 351 12 24 0810 216 486 500kg 135 459 127 1987 (m 3 / / ) 0566 2266 5947 9 18kg 0057 0425 1019 18 45 0142 0566 1358 45 675 0198 0708 2038 675 945 0283
(1.2) T D = 0 T = D = 30 kn 1.2 (1.4) 2F W = 0 F = W/2 = 300 kn/2 = 150 kn 1.3 (1.9) R = W 1 + W 2 = = 1100 N. (1.9) W 2 b W 1 a = 0
1 1 1.1 1.) T D = T = D = kn 1. 1.4) F W = F = W/ = kn/ = 15 kn 1. 1.9) R = W 1 + W = 6 + 5 = 11 N. 1.9) W b W 1 a = a = W /W 1 )b = 5/6) = 5 cm 1.4 AB AC P 1, P x, y x, y y x 1.4.) P sin 6 + P 1 sin 45
G_CM3050S_IFU_2v0G_ja
CM3050S 14044385108 - G 2.0 G - 11/2017 Leica Biosystems Nussloch GmbH Leica Biosystems Nussloch GmbH Web Cam Leica Biosystems Nussloch GmbH Heidelberger Str. 17-19 69226 Nussloch Germany Tel.: +49 -
untitled
I 3 2 4 2. 4 2. 2 4 2. 3 4 2. 4 4 2. 5 4 2. 6 4 2. 7 5 2. 8 5 2. 9 5 3. 8 3. 8 3.2 8 3.3 0 3.4 0 3.5 4 3.6 6 3.7 7 3.8 Lagmur 22 3.9 Freudlch 26 3.0 29 3. 30 3.2 36 4. 37 4. 37 4.2 37 4.3 39 4.4 4 5. DNA
油圧1.indd
ff ff ff ff f f ff ff ff f f f f f f f f f f f f f f ff ff! f f f f f f f ff ff f f ff f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f S 9 M6 M6 M6 M. 6 6 R/ P M. M. M. M. f f f 96 f f f M.
(35H-3).pm
ff f f f f f f f f f f f f f ff ff ff f f ff ff ff f ff ff! f f f f f f f f f f f f f ff ff f f ff f f f f f f f f f f f f f f f f f f f f f S f f f f f f 9 M6 M6 M6 M. M. M. M. M. 6 6 9 R/ R/ P M. M.
PII S (96)
C C R ( 1 Rvw C d m d M.F. Pllps *, P.S. Hp I q G U W C M H P C C f R 5 J 1 6 J 1 A C d w m d u w b b m C d m d T b s b s w b d m d s b s C g u T p d l v w b s d m b b v b b d s d A f b s s s T f p s s
C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up
九州支部卒後研修会症例
血液検査研修会 ( 第 25 回 ) 検査の異常から探る! 造血器腫瘍へのアプローチ 症例提示 症例 1~8 - 症例発表者 - 症例 1 藤崎恵熊本医療センター 症例 2 荒木敏造浜の町病院 症例 3 古城剛鹿児島大学病院 症例 4 佐々木高太郎都城健康サービスセンター 症例 5 矢田佳愛 大分県立病院 症例 6 下田博臣 健康保険諫早総合病院 症例 7 堤陽子 佐賀県医療センター好生館 症例 8
日本呼吸器学会雑誌第44巻第10号
β Table1 Laboratoryfindingsonthefirstvisit Hematology WBC Neut. Lyn. Mon. Eos. Bas. RBC Hb Ht Plate 5,650 /μl 79.2 % 14.9 % 3.9 % 1.8 % 0.2 % 418 10 4 /μl 12.5g/dl 38.4 % 21.2 10 4 /μl Serology CRP IgG
ml ml ml mg ml ml mm mm mm mm mm mm mm mm mm mm mm ml mmhg mmhg ml Acetylcholine ml mg mm mm mm mm mm mm ope ++ Uribe Davis S H S S : : : : : : : : : G
V(x) m e V 0 cos x π x π V(x) = x < π, x > π V 0 (i) x = 0 (V(x) V 0 (1 x 2 /2)) n n d 2 f dξ 2ξ d f 2 dξ + 2n f = 0 H n (ξ) (ii) H
199 1 1 199 1 1. Vx) m e V cos x π x π Vx) = x < π, x > π V i) x = Vx) V 1 x /)) n n d f dξ ξ d f dξ + n f = H n ξ) ii) H n ξ) = 1) n expξ ) dn dξ n exp ξ )) H n ξ)h m ξ) exp ξ )dξ = π n n!δ n,m x = Vx)
日本呼吸器学会雑誌第48巻第6号
Fig.1 Cutaneousfindingsandpathologicalfindingsofatransbronchiallungbiopsy(TBLB)andlichenifiedeczemaoftherightforearm.Thepatienthadlichenifiedeczemaonhisextremitiesandbodytrunk (1a:rightforearm,1b:leftthigh).Therewasinfiltrationoftheinflammatorylymphocytes,edemaandabrasioninthetype2alveolarepithelium
パネルディスカッション 2 Q 専門領域について選択してください 1. 消化器内科 2. 消化器外科 3. 放射線科 1% 4% 3% 21% 4. その他の医師 5. その他 ( 医師以外 ) 71%
パネルディスカッション 2 Q 専門領域について選択してください 1. 消化器内科 2. 消化器外科 3. 放射線科 1% 4% 3% 21% 4. その他の医師 5. その他 ( 医師以外 ) 71% 第 49 回日本膵臓学会大会 2018.06.29. パネルディスカッション 2 症例 1 JA 尾道総合病院消化器内科 南智之, 花田敬士, 清水晃典, 福原基允, 横出正隆 Onomichi General